Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
8,741
result(s) for
"Emma D"
Sort by:
The joy of yoga : fifty sequences for your home and studio practice
The Joy of Yoga offers short sequences that readers can perform while seated on airplanes, in taxi cabs, standing at the bus stop, or even while waiting for water to boil. In addition, it also includes sequences to help with daily aches, pains, and annoyances, such as tired feet, sensitive wrists, neck and shoulder tension, lower back pain, anxiety, and even heartbreak. Weekend gardeners, cyclists, runners, musicians, and waiters/waitresses will also find exercises that will help ease the tension in their muscles after long hours of work or play. The Joy of Yoga will also provide step-by-step instructions on asana (postures) and pranayama (breathing techniques) for fifty sequences List the benefits of each sequence and include helpful information about modifications for poses encourage readers to create sequences on their own, using the sequences in the book as starting points.
Book
Disitamab Vedotin: First Approval
Disitamab vedotin (Aidixi
®
) is an antibody–drug conjugate comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent monomethyl auristatin E. Disitamab vedotin is being developed by RemeGen for the treatment of solid tumours, including gastric cancer; Seagen has the right to develop disitamab vedotin globally outside of RemeGen’s territory. In June 2021, disitamab vedotin received its first Biologics License Application (BLA) approval in China for the treatment of patients with HER2-overexpressing (defined as IHC2+ or 3+) locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least two systemic chemotherapy regimens. Disitamab vedotin as monotherapy or combination therapy is also in clinical development for the treatment of other solid tumours globally, including urothelial cancer in China and the USA, and biliary tract cancer, non-small cell lung cancer and HER2-positive and HER2-low expressing breast cancer in China. This article summarizes the milestones in the development of disitamab vedotin leading to this first approval for locally advanced or metastatic gastric cancer.
Journal Article
Yoga twists and turns : 50 sequences to take your practice to the next level
\"A series of warm-ups, yoga postures, and stretches to lead to specific intermediate and advanced yoga postures\"--Page 4 of cover.
Book
Polatuzumab Vedotin: First Global Approval
Polatuzumab vedotin (polatuzumab vedotin-piiq; Polivy™) is an antibody–drug conjugate comprising a monoclonal antibody against CD79b (a B cell receptor component) covalently conjugated to the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE) via a cleavable linker. After binding to CD79b on the B-cell surface, polatuzumab vedotin is internalized and the linker is cleaved, releasing MMAE into the cell, where it inhibits division and induces apoptosis. Polatuzumab vedotin is being developed by Genentech (a subsidiary of Roche) for the treatment of haematological malignancies. In June 2019, the US FDA granted accelerated approval to polatuzumab vedotin, in combination with bendamustine plus rituximab, for the treatment of adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two prior therapies. Use of the compound in combination with bendamustine plus rituximab is also under regulatory review for relapsed/refractory DLBCL in the EU and is in ongoing phase 1b/2 development in this setting or relapsed/refractory follicular lymphoma (FL) in several countries. Various other polatuzumab vedotin combination therapy regimens are also in phase 1b/2 development for relapsed/refractory non-Hodgkin lymphoma (NHL) [including DLBCL and FL] or in phase 2 or 3 development for previously untreated DLBCL, while polatuzumab vedotin monotherapy has been in phase 1 development for relapsed/refractory B-cell NHL in Japan. This article summarizes the milestones in the development of polatuzumab vedotin leading to this first approval for its use in combination with bendamustine plus rituximab for relapsed/refractory DLBCL.
Journal Article
Fexinidazole: First Global Approval
Fexinidazole Winthrop (hereafter referred to as fexinidazole) is a DNA synthesis inhibitor developed by the Drugs for Neglected Diseases initiative (DNDi), in collaboration with Sanofi, for the oral treatment of human African trypanosomiasis (HAT) [commonly known as ‘sleeping sickness’] and Chagas’ disease. The drug is a 5-nitroimidazole derivative first discovered by Hoechst AG (now part of Sanofi) and was identified by the DNDi in 2005 as having activity against
Trypanosoma brucei gambiense
and
T. b. rhodesiense
. Under Article 58 of Regulation (EC) no. 726/2004 (a regulatory mechanism for reviewing new medicines destined for use outside of the EU), fexinidazole has been granted a positive opinion by the EMA for the treatment of both the first-stage (haemo-lymphatic) and second-stage (meningo-encephalitic) of HAT due to
T. b. gambiense
(g-HAT) in adults and children aged ≥ 6 years and weighing ≥ 20 kg. This approval will facilitate and support marketing authorization application in endemic countries in 2019; following registration, fexinidazole will be distributed via the WHO to endemic countries for g-HAT. Phase 3 evaluation of fexinidazole for g-HAT is ongoing in the Democratic Republic of the Congo and Guinea and the drug is also in development for Chagas’ disease, with a study currently ongoing in Spain. Clinical development for visceral leishmaniasis is discontinued. This article summarizes the milestones in the development of fexinidazole leading to this first approval for g-HAT.
Journal Article
Casirivimab/Imdevimab: First Approval
Casirivimab/imdevimab (Ronapreve™; REGEN-COV™) is a co-packaged combination of two neutralizing immunoglobulin gamma 1 (IgG1) human monoclonal antibodies (casirivimab and imdevimab) against the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19). Casirivimab/imdevimab received its first emergency use authorization for the treatment of COVID-19 in November 2020 in the USA, with similar authorizations subsequently granted in various other countries, including India, Canada, and Switzerland. In February 2021, casirivimab/imdevimab was granted a positive scientific opinion in the EU for the treatment of COVID-19. In July 2021, casirivimab/imdevimab received its first approval in Japan for the treatment of mild or moderate COVID-19, followed in August 2021 by its conditional approval for the prophylaxis and treatment of acute COVID-19 infection in the UK. The combination was also granted provisional determination in Australia in August 2021, indicating its eligibility to be considered for provisional registration for COVID-19 treatment and prevention. This article summarizes the milestones in the development of casirivimab/imdevimab leading to these first approvals for COVID-19.
Journal Article
ما معنى أن أكون رائد أعمال مجازفا ؟
يتناول الكتاب (ما معنى أن أكون رائد أعمال مجازفا ؟) والذي قام بتأليفه (رنا دي أوريو، إيما د. درايدن) في حوالي (30 صفحة) من القطع المتوسط موضوع (النجاح الإداري وريادة الأعمال وثقافة الأطفال) وهو مؤلف مخصص وكتاب يحث الطفل على \"المجازفة\" وعدم الانجراف وراء الشعور بالخوف أو الفشل فهذا هو التميز بعينه ! بنص بسيط يستعرض الكاتب كيف يكون الإنسان رائد أعمال مجازف : فهذا لا يعني بالضرورة كسب المال الكثير ولا امتلاك متجرك الخاص، المطلوب أن تؤمن بحلمك، تقاتل من أجله، تتعلم تتحلى بالمرونة والتواضع اللازمين لتخطي العوائق.
Book
Belzutifan: First Approval
Belzutifan (Welireg™) is an oral small molecule inhibitor of hypoxia-inducible factor (HIF)-2α being developed by Peloton Therapeutics for the treatment of solid tumours, including renal cell carcinoma (RCC) with clear cell histology (ccRCC) and von Hippel–Lindau (VHL) disease-associated RCC. In August 2021, belzutifan received its first approval in the USA for the treatment of patients with VHL disease who require therapy for associated RCC, central nervous system (CNS) haemangioblastomas or pancreatic neuroendocrine tumours (pNET), not requiring immediate surgery. Clinical studies of belzutifan (as monotherapy or combination therapy) in other indications, including ccRCC, pNET and phaeochromocytoma/paraganglioma, are also underway in various countries. This article summarizes the milestones in the development of belzutifan leading to this first approval for certain VHL disease-associated tumours.
Journal Article